NAMPT INHIBITION SELECTIVELY TARGETS MDS MYELOBLASTS IN HIGH-RISK MDS WITH MONOSOMY 7 OR DEL(7Q)

Nemo Ikonen,[1,2] Tanja Ruokoranta,[1,3] Salla Hyyppä,[1] Ella Sinervuori,[1,2] Juho J. Miettinen,[1,2] Joseph Saad,[1,2] Markus Vähä-Koskela,[1,2] and Caroline A. Heckman[1,2]

[1]Institute for Molecular Medicine Finland - FIMM, Helsinki Institute of Life Science, University of Helsinki, Finland

[2]iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki and Helsinki University Hospital, Finland

[3]Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland

Statement of prior presentation: Presented in poster form at the 2024 EHA Hybrid Conference, Madrid, 14 June 2024.

Data sharing statement: The data generated or analyzed during this study are included in this manuscript and its supplementary files. RNA counts data have been deposited to Zenodo: link and DOI will be provided following manuscript acceptance. All other relevant data to the current study are available from the corresponding author (Caroline Heckman, caroline.heckman@helsinki.fi) on reasonable request.

Correspondence:

Caroline Heckman, PhD, Institute for Molecular Medicine Finland, University of Helsinki, Tukholmankatu 8 (P.O. Box 20), FI-00290 Helsinki, Finland, Telephone: +358 50 4156769, Email: caroline.heckman@helsinki.fi

Short title: NAMPT inhibitor sensitivity in MDS with -7/-7q

Main text word count: 1221 / 1200

Figures: 2/2 **Supplementary Tables:** 9

References: 19 / 25 **Supplementary Figures:** 5

Abstract

Monosomy 7 and deletion of the q arm of chromosome 7 (-7/-7q) are high-risk markers in myelodysplastic syndromes (MDS). We previously showed that blasts with -7/-7q from patients with acute myeloid leukemia (AML) are exceptionally sensitive to NAMPT inhibitors, with the sensitivity caused by *NAMPT* gene haploinsufficiency as a result of -7/-7q. The objective of this study was to investigate whether blasts from patients with -7/-7q MDS are similarly susceptible to NAMPT inhibition. We first assessed the sensitivity of MDS samples to NAMPT inhibition using data from *ex vivo* cell viability-based drug sensitivity assays, which showed that MDS samples were more sensitive to NAMPT inhibition compared to healthy donor samples and that a MDS sample with -7/-7q was the most sensitive to NAMPT inhibition. We further evaluated the efficacy of NAMPT inhibitors on different leukemic and healthy cell populations using a flow cytometry-based drug sensitivity assay. Leukemic cell populations from -7/-7q samples were highly sensitive to NAMPT inhibition and were more sensitive than cells from non -7/-7q samples. Additionally, we combined NAMPT inhibitor KPT-9274 with BCL2 inhibitor venetoclax, which resulted in significantly more leukemic cell killing than the NAMPT inhibitor alone. MDS samples with -7/-7q also showed significantly lower *NAMPT* expression compared to the non -7/-7q samples, indicative of haploinsufficient gene expression profile. The results from this study show that NAMPT inhibitors can effectively target -7/-7q MDS blasts *ex vivo* and the findings are in line with earlier studies in AML, suggesting that patients with high-risk MDS, especially those with -7/-7q, could benefit from NAMPT inhibitors.

Research letter

Myelodysplastic syndromes (MDS) are a heterogenous clonal disorder characterized by the accumulation of aberrant hematopoietic stem cells in the bone marrow (BM) and peripheral blood, cytopenia, recurrent genetic abnormalities, and a risk of progression to acute myeloid leukemia (AML)[1]. MDS patients in high-risk groups, according to the IPSS-R classification[2], currently lack effective treatment options as the median survival with the current standard of treatment, consisting of hypomethylating agents, remains under 2 years[3,4]. High risk markers monosomy 7 and deletion of the q arm of chromosome 7 (-7/-7q) are associated with poor prognosis, shorter survival and increased risk of AML progression, and are present in approximately 10% of patients with MDS[3,5,6].

Nicotinamide phosphoribosyl transferase (NAMPT), encoded by the NAMPT gene at chromosome 7q22.3, is the rate limiting enzyme in the nicotinamide adenine dinucleotide (NAD+) salvage pathway. The NAD+ salvage pathway is essential for cancer cell survival, since rapidly dividing cells require NAD+ for energy metabolism, redox reactions, signaling pathways, DNA repair and calcium homeostasis[7]. Multiple NAMPT inhibitors have been developed over the years such as FK866 (daporinad), KPT-9274 and OT-82, which have shown good efficacy in preclinical studies of hematological malignancies as they effectively target cancer cell metabolism by blocking the NAD+ pathway[8–10]. However, none of these inhibitors has been approved and only KPT-9274 is being clinically investigated for efficacy in AML (NCT04914845).

Ex vivo drug sensitivity testing, in which blasts derived from AML or MDS patients were treated with a panel of inhibitors is a useful method to screen for potentially responding patients, and have been shown to predict clinical responses[11,12]. Using a similar approach, we have previously showed that AML blasts with -7/-7q are exceptionally sensitive to NAMPT inhibitors, with the sensitivity caused by NAMPT gene haploinsufficiency as a result of -7/-7q[13]. This was replicated in a more recent study by Senagolage et al[14], confirming an association between NAMPT inhibitor sensitivity and -7/-7q in AML. The objective of our study was to investigate whether blasts from MDS patients with -7/-7q are similarly susceptible to NAMPT inhibition.

A total 41 samples from MDS patients were included in the study, of which 10 had -7/-7q. Patient characteristics are described in detail in **Supplemental Table 1**, and the workflow

is illustrated in **Figure 1A**. Methods are described in full in the **Supplemental Material.** We first assessed the bulk cell viability-based drug sensitivity screening results from MDS patient samples and compared it to data from healthy donors that were screened as part of the ISM2 project and our previous publication[13,15]. Freshly isolated mononuclear cells (MNCs) from MDS patient samples and healthy donors were incubated with NAMPT inhibitor daporinad for 72 hours, and cell viability was measured using the CellTiter-Glo (CTG, MDS n=6, healthy n=14) and/or Celltox Green (CTxG, MDS n=7, healthy n=5) assays. Dose response curves (**Figure 1B–C**) were summarized as drug sensitivity scores (DSS), where 0 indicates no response and 50 indicates the maximal response **(Figure 1D–E**, **Supplemental Tables 2–3**). Overall, MDS samples were significantly more sensitive to NAMPT inhibition compared to the healthy samples in the CTG assay (**Supplemental Figure 1A**), indicative of an actionable therapeutic window and in line with previous studies in AML[8,16,17]. The sample carrying -7/-7q was found to be the most responsive sample to NAMPT inhibition (**Figure 1D**). There was no significant difference between the MDS and healthy samples in CTxG assay (**Supplemental Figure 1B**), however, the sample with -7/-7q had the highest response compared to the rest of the MDS samples and the healthy samples (**Figure 1E**). In general, -7/-7q MDS samples showed similar NAMPT inhibitor sensitivity profiles as previously observed in -7/-7q AML[13].

To assess if the -7/-7q MDS samples express less *NAMPT* due to *NAMPT* gene haploinsufficiency, we first enriched CD34+CD38- cells from 30 MDS patient samples (-7/-7q n=5, non -7/-7q n=25) by FACS and then performed RNA sequencing on the enriched population. Gene expression analysis showed that samples with -7/-7q had significantly lower *NAMPT* expression, indicating a haploinsufficient gene expression profile (**Figure 1F**, **Supplemental Table 4**).

To investigate NAMPT inhibitor activity in different cell subpopulations, we performed flow cytometry-based drug sensitivity analysis. BM MNCs from MDS patients with (n=8) and without (n=12) -7/-7q were incubated with NAMPT inhibitors daporinad and KPT-9274 for 72 hours (**Supplemental Table 5**). Subsequently, the cells were stained with an antibody panel (**Supplemental Table 6**) to identify different hematopoietic and myeloid cell populations, and with viability markers to separate viable and dead cells. DSSs were

calculated for each cell population from the dose-response curves for each sample (**Supplemental Figure 2**, **Supplemental Table 7**). We observed that NAMPT inhibitors effectively target the different myeloblast populations in MDS samples. At the cell subpopulation level, CD34+, CD117+, CD34+CD117+, CD34+CD38- and CD34+CD38+ blasts from -7/-7q MDS were significantly more sensitive to NAMPT inhibition by daporinad compared to non -7/-7q MDS blasts (**Figure 2A**). Other cell subtypes were also sensitive to NAMPT inhibition, but there was no significant difference between samples with and without -7/-7q. Similar trends were observed for the CD34+CD38- and CD34+CD38+ populations when tested for sensitivity to KPT-9274, however, the results were not significant (**Figure 2B**). When compared to the CD3+ T lymphocyte cells representing a healthy cell population control, the CD34+, CD34+CD117+ and CD34+CD38+ cell populations were significantly more sensitive to daporinad in -7/-7q samples (**Supplemental Figure 3A**). Additionally, the CD34+CD38+ cell population was significantly more sensitive than the CD14+ monocytic population. For KPT-9274, the CD34+CD38+ cell population was more sensitive compared to CD3+ T lymphocytes, while CD34+, CD34+CD117+ and CD34+CD38+ were more sensitive compared to CD14+ monocytic population in the -7/-7q samples (**Supplemental Figure 3B**). These results indicate that the cell populations with a leukemic phenotype, particularly CD34+CD38+, are more sensitive to NAMPT inhibition, in-line with our previous study[13].

To assess NAMPT inhibitor efficacy with clinically relevant drug combination partners and to increase the efficacy of KPT-9274 as it did not show as good response in comparison to daporinad in the -7/-7q samples, we performed flow cytometry-based drug sensitivity assay of KPT-9274 in three different drug combinations: venetoclax, azacitidine and cytarabine. We observed that the combination of KPT-9274 at 1000 nM and venetoclax at 10 nM was significantly more cytotoxic in CD34+CD38- cells in -7/-7q samples compared to KPT-9274 alone and had a significant difference between -7/-7q and non -7/-7q samples (**Figure 2C**). The addition of 300 nM azacitidine or 100 nM cytarabine did not significantly decrease the cell viability (**Supplemental Table 8**, **Supplemental Figure 3C–D**).

In general, the results from this study show that NAMPT inhibitors are highly active in -7/-7q MDS patient samples and the findings are in line with earlier studies in AML[13,14], suggesting that MDS patients, especially those with -7/-7q could also benefit from NAMPT inhibitors. This increased sensitivity to NAMPT inhibitors could be explained by the *NAMPT* haploinsufficiency. This increased sensitivity to NAMPT inhibitors could be explained by the *NAMPT* haploinsufficiency, similarly as the haploinsufficiency of *CSNK1A1* in del(5q) MDS induces sensitivity to lenalidomide[18]. A major limitation of this study is the small sample size, but these results support investigating NAMPT inhibitors in a larger cohort of MDS samples and in combination with clinically relevant inhibitors such as venetoclax. Although several first generation NAMPT inhibitors are no longer being clinically assessed, high-risk MDS patients, especially those bearing -7/-7q, could benefit from the next generation of NAMPT inhibitors such as RPT1G[19].

Acknowledgements

The authors thank the patients and clinics who made this study possible. The authors also thank the Finnish Hematology Registry and Clinical Biobank (FHRB) for providing the samples and clinical information. Instruments, drug plate preparation and part of the flow cytometry analysis were carried out by the FIMM High Throughput Biomedicine Unit, and library preparation and RNA sequencing were performed by Biomedicum Functional Genomics Unit and FIMM Genomics NGS Sequencing unit, which all are hosted by the University of Helsinki and supported by HiLIFE and Biocenter Finland. Cell sorting and analysis were performed at the HiLife Flow Cytometry Unit, University of Helsinki. N.I. is a Ph.D. candidate at the University of Helsinki. This work is submitted in partial fulfillment of the requirement for the Ph.D. The authors would like to express gratitude to Minna Suvela and Alun Parsons for their role in processing the samples for the study and to Natalia Mokrzecka for her help with the flow cytometry. This work was supported by the University of Helsinki, Cancer Foundation Finland, the Academy of Finland (grants 334781, 1320185) (C.A.H.), (grant 334273), the Sigrid Jusélius Foundation, Veritautien tutkimussäätiö (N.I.), Ida Montin Foundation (N.I.) and the Finnish Cultural Foundation (N.I.).

Authorship

Contribution: N.I., T.R., S.H., E.S., J.M. and J.S. planned and conducted experiments. N.I. analyzed and interpreted the data. N.I., and C.A.H wrote the manuscript. M.V.-K. and C.A.H. provided leadership and funding. All authors read and approved the manuscript.

Conflict of Interest Disclosure: C.A.H. has received research funding for unrelated work from Oncopeptides, IMI2 projects HARMONY and HARMONY PLUS, WNTResearch, Orion, Kronos Bio, Novartis, Celgene, and Zentalis Pharmaceuticals; has been awarded honoraria from Amgen and consultancy fees from Autolus. M.V.-K has received research funding from Immunocore UK for unrelated work. Other authors declare no conflicts of interest.

Correspondence: Caroline Heckman, Institute for Molecular Medicine Finland, University of Helsinki, FI-00290, Helsinki, Finland, email: caroline.heckman@helsinki.fi

References

1. Cazzola M. Myelodysplastic Syndromes. *N Engl J Med*. 2020;383(14):1358-1374. doi:10.1056/NEJMra1904794

2. Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for Myelodysplastic Syndromes. *Blood*. 2012;120(12):2454-2465. doi:10.1182/blood-2012-03-420489

3. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *Lancet Oncol*. 2009;10(3):223-232. doi:10.1016/S1470-2045(09)70003-8

4. Kantarjian H, Issa JPJ, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes. *Cancer*. 2006;106(8):1794-1803. doi:10.1002/cncr.21792

5. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. *Blood*. 2007;110(13):4385-4395. doi:10.1182/blood-2007-03-082404

6. Schanz J, Tüchler H, Solé F, et al. New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. *J Clin Oncol*. 2012;30(8):820-829. doi:10.1200/JCO.2011.35.6394

7. Ying W. NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. *Antioxid Redox Signal*. 2008;10(2):179-206. doi:10.1089/ars.2007.1672

8. Nahimana A, Attinger A, Aubry D, et al. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. *Blood*. 2009;113(14):3276-3286. doi:10.1182/blood-2008-08-173369

9. Mitchell SR, Larkin K, Grieselhuber NR, et al. Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia. *Blood Adv*. 2019;3(3):242-255. doi:10.1182/bloodadvances.2018024182

10. Korotchkina L, Kazyulkin D, Komarov PG, et al. OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis. *Leukemia*. 2020;34(7):1828-1839. doi:10.1038/s41375-019-0692-5

11. Spinner MA, Aleshin A, Santaguida MT, et al. Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms. *Blood Adv*. 2020;4(12):2768-2778. doi:10.1182/bloodadvances.2020001934

12. Kytölä S, Vänttinen I, Ruokoranta T, et al. Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial. *Blood*. 2025;145(4):409-421. doi:10.1182/blood.2024024968

13. Eldfors S, Saad J, Ikonen N, et al. Monosomy 7/del(7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemia. *Blood Adv*. 2024;8(7):1621-1633. doi:10.1182/bloodadvances.2023010435

14. Senagolage MD, Blaylock HZ, Khan S, Skuli SJ, Carroll MP, McNerney ME. NAMPT haploinsufficiency is a collateral lethal therapeutic vulnerability in high-risk myeloid malignancies with TP53 inactivation. *Blood Neoplasia*. 2025;2(3):100119. doi:10.1016/j.bneo.2025.100119

15. Malani D, Kumar A, Brück O, et al. Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. *Cancer Discov*. 2022;12(2):388-401. doi:10.1158/2159-8290.CD-21-0410

16. Jones CL, Stevens BM, Pollyea DA, et al. Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells. *Cell Stem Cell*. 2020;27(5):748-764.e4. doi:10.1016/j.stem.2020.07.021

17. Mitchell SR, Larkin K, Grieselhuber NR, et al. Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia. *Blood Adv*. 2019;3(3):242-255. doi:10.1182/bloodadvances.2018024182

18. Krönke J, Fink EC, Hollenbach PW, et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. *Nature*. 2015;523(7559):183-188. doi:10.1038/nature14610

19. Crimmins G, Wu M, Roushar F, et al. The Hyperbolic NAMPT Inhibitor RPT1G Synergizes with BCL-2 Family Inhibitors and Helps Overcome Venetoclax Resistance in Acute Myeloid Leukemia Cells. *Blood*. 2024;144:4134. doi:10.1182/blood-2024-197972

Figure legends

Figure 1. MDS samples are sensitive to NAMPT inhibition. A) Illustration of the experimental workflow. B) Dose response curves for CellTiter-Glo -based and C) CellTox Green -based bulk cell viability assays. Samples were treated with daporinad in 5 concentrations for 72 hours. D) Daporinad Drug sensitivity score for MDS and healthy samples for CellTiter-Glo. Data for healthy samples (n=14) from previous publications were summarized as one curve with standard deviations. E) CellTox Green assays. Data for healthy samples (n=5) from previous publications were summarized as one score with standard deviation. F) *NAMPT* gene expression z-scores were compared between -7/-7q (n=5) and non -7/-7q MDS samples (n=25) using a the two-sample t-test.

Figure 2. Flow cytometry-based drug sensitivity screening shows that MDS samples with -7/-7q are highly sensitive to NAMPT inhibition. Drug sensitivity scores for the different cell populations for A) daporinad and B) KPT-9274. MDS samples with (n=8) and without (n=12) -7/-7q were incubated with the inhibitors for 72 hours and dose response curves were summarized as DSSs. Higher DSS indicates sensitivity. Samples with -7/-7q were compared to those without -7/-7q using a two-sample t-test. C) Comparison of cell viability between single agents and drug combination of 1000 nM of KPT-9274 and 10 nM of venetoclax in CD34+CD38- cells in -7/-7q (n=5) and non -7/-7q (n=5) samples. Samples were treated with the inhibitors for 72 hours, after which the cells were stained with detection antibodies to separate different cell types. Comparisons were done using a two-sample t-test and *P* values were adjusted using the Benjamini-Hochberg method.

Figure 1.


A)
MDS patient samples n=41
Mononuclear cells
72-hour incubation with the drug panel
Bulk viability readout (CTG and CTxG) n=7
Flow cytometry based viability readout n=20
CTG and Flow assay
Cell viability (%)
DSS low resistant
DSS high sensitive
Concentration [M]
CTxG assay
Cell death (%)
DSS high sensitive
DSS low resistant
Concentration [M]
Cell sorting for CD34+CD38- cells
RNA sequencing n=30
B)
CellTiter-Glo
Cell viability (%)
Daporinad [nM]
-7/-7q
Non -7/-7q
Healthy
C)
CellTox Green
Cell death (%)
Daporinad [nM]
-7/-7q
Non -7/-7q
Healthy
D)
CellTiter-Glo
DSS
MDS.31
MDS.13
MDS.37
MDS.6
MDS.36
MDS.1
Healthy
-7/-7q
Non -7/-7q
Healthy
E)
CellTox Green
DSS
MDS.31
MDS.13
Healthy
MDS.1
MDS.37
MDS.6
MDS.36
MDS.27
-7/-7q
Non -7/-7q
Healthy
F)
P = .018
NAMPT expression z-score
-7/-7q n=5
Non -7/-7q n=25

Figure 2.


A)
Flow cytometry assay
Daporinad DSS
-7/-7q
Non -7/-7q
***
**
***
*
*
CD34+
CD117+
CD38+
CD34+CD117+
CD34+CD38-
CD34+CD38+
CD14+
CD3+
B)
Flow cytometry assay
KPT-9274 DSS
-7/-7q
Non -7/-7q
CD34+
CD117+
CD38+
CD34+CD117+
CD34+CD38-
CD34+CD38+
CD14+
CD3+
C)
CD34+CD38- cells
Cell viability (%)
P = .034
P = .025
-7/-7q
Non -7/-7q
KPT-9274 1000nM
Venetoclax 10nM
KPT-9274 1000nM Venetoclax 10nM